Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

November 6, 2020 7:00 AM EST

 SER-301 is designed to target the physiological triggers of inflammation believed to be central to the underlying pathology of ulcerative colitis  

 Program represents Seres second active clinical program targeting ulcerative colitis, in addition to its ongoing SER-287 Phase 2b study

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq:... More